Diligence memo · auto-generated · as of July 2, 2026
Aquyre Biosciences Inc
Aquyre Biosciences Inc looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Aquyre Biosciences Inc operates in Biotech / Pharma, based in WESTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aquyre Biosciences Inc has raised $29M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2021-09-29.
Most recent recorded round closed around 2023-09-29.
Valuation (modeled)modeled
Provath models Aquyre Biosciences Inc at approximately $31M (range $6.6M–$64M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.12× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 2.8 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 82% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Carbon Biosciences, Inc., Slingshot Biosciences, Inc., Nueva Bio LLC, Telesis Bio Inc., Turn Biotechnologies, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.